Table 1.
Serum | Days post symptom onset | Euroimmun IgG | Epitope IgG | ||
---|---|---|---|---|---|
Index | Reactive | Index | Reactive | ||
1 | 14 | 1.3 | + | 2.6 | + |
2 | 12 | 6.0 | + | 3.5 | + |
3 | 17 | 10.2 | + | 3.9 | + |
4 | 16 | 14.9 | + | 4.5 | + |
5 | 5 | 0.2 | − | 1.2 | + |
6 | 19 | 8.6 | + | 4.4 | + |
7 | 17 | 7.1 | + | 4.1 | + |
8 | 10 | 5.1 | + | 2.0 | + |
9 | 14 | 6.8 | + | 3.1 | + |
10 | 6 | 0.2 | − | 1.1 | + |
11 | - | 5.6 | + | 0.9 | +/− |
12 | - | <0.8 | − | 1.3 | + |
13 | 9 | 0.7 | − | 1.1 | + |
14 | 20 | 3.6 | + | 2.9 | + |
15 | 13 | 0.4 | − | 2.0 | + |
16 | 13 | 0.5 | − | 0.9 | − |
17 | 11 | 0.3 | − | 0.8 | − |
18 | 10 | 0.2 | − | 0.7 | − |
19 | 14 | 0.9 | +/− | 1.2 | + |
20 | 10 | 0.4 | − | 1.5 | + |
21 | 11 | 0.5 | − | 2.0 | + |
22 | 10 | 0.3 | − | 0.6 | − |
23 | 17 | 7.6 | + | 4.2 | + |
24 | 14 | 3.5 | + | 3.3 | + |
25 | 13 | 1.5 | + | 2.9 | + |
26 | 17 | 14.2 | + | 4.4 | + |
27 | 13 | 0.5 | − | 1.9 | + |
28 | 14 | 9.2 | + | 4.6 | + |
29 | 13 | 3.9 | + | 2.8 | + |
30 | 16 | 3.4 | + | 4.6 | + |
31 | 15 | 10.7 | + | 3.6 | + |
32 | 6 | 0.5 | − | 1.1 | + |
33 | 11 | 0.4 | − | 1.8 | + |
34 | 12 | 0.6 | − | 2.5 | + |
35 | 14 | 3.7 | + | 4.1 | + |
36 | 20 | 11.6 | + | 4.2 | + |
37 | 7 | 0.7 | − | 1.2 | + |
38 | 8 | 1.7 | + | 1.9 | + |
39 | 7 | 0.3 | − | 0.7 | − |
40 | 9 | 3.4 | + | 2.2 | + |
41 | 18 | 10.3 | + | 4.1 | + |
42 | 17 | 10.3 | + | 4.6 | + |
Serum samples from 20 individuals were collected at different time points post onset of COVID-19 symptoms, were screened using two ELISA assays (Euroimmun or Epitope). The serum numbers correspond to those of Figures 4 and S3. IgG index values were calculated by dividing the O.D. of the serum sample by a reference O.D. control, and ratios were interpreted using the following criteria as recommended by the manufacturer: Negative (−) <0.8, Indeterminate (+/−) 0.8–1.1, Positive (+) ≥1.1.